C ardiac hypertrophy (CH) is a major risk factor for cardiac death and commonly precedes the development of heart failure (HF). This is motivating the search for novel pharmacological strategies to prevent the development and/or regress CH. Although the signaling pathways leading to myocardial hypertrophy are complex, one important set of pathways involves the mitogen-activated protein kinases (MAPKs). 1 MAPKs phosphorylate numerous substrates, including nuclear transcription factors that activate the expression of different genes. The Na ϩ -H ϩ exchanger (NHE) is a common downstream effector of this cascade 2-4 and has been implicated in different models of hypertrophy, such as "hypertensive" myocardium, aortic constrictioninduced hypertrophy, and postinfarction myocardial hypertrophy. [5] [6] [7] [8] Interestingly, stretch-induced hypertrophy of cultured neonatal cardiomyocytes is also accompanied by an increase in MAPK activity 6, 8 and NHE activation. Furthermore, stretch-induced MAPK stimulation is partially prevented by inhibition of NHE activity. 6 The article published in this issue of Circulation Research by Engelhardt et al 9 reports another example of a link between NHE activity and cellular growth, employing a different experimental model of CH induced by overexpression of ␤ 1 -adrenergic receptors in transgenic mice. CH, fibrosis, and failure induced by this model were prevented by NHE inhibition. The overstimulation of ␤ 1 -adrenergic receptors with isoproterenol is perhaps a similar experimental model of hypertrophy that has been extensively studied before 10 -13 and reported to be mediated by p41/p42-MAPK activation. 13 Karmazyn's group 7 reported that the inhibition of NHE activity attenuated the hypertrophy that follows myocardial infarction. Camilión de Hurtado et al 14 recently reported that chronic NHE blockade in vivo induces regression of CH in spontaneously hypertensive rats (SHR) without a significant decrease in arterial pressure. The in vivo blockade of NHE also decreases the cellular proliferation detected in vessels from diabetic rats. 15 Taken together, these findings provide compelling evidence of a common role played by NHE in different models of myocardial hypertrophy.
Which would be the relationship between NHE activity and myocardial hypertrophy? Perhaps the most convincing demonstration of a signaling role for NHE activation in cellular growth is found in sea urchin eggs, where fertilization is followed by NHE activation, and cellular growth is precluded if NHE activation is prevented. 16 It has been previously demonstrated that [Na ϩ ] i increases in hypertrophied myocardium. 27 Furthermore, in isolated myocytes and vascular smooth muscle cells, Na ϩ has a direct effect of increasing protein synthesis and decreasing protein degradation. 28 Epidemiological and basic studies support the notion that Na ϩ is an independent factor for the development of salt-induced CH. 29, 30 Frohlich and colleagues reported that a high Na ϩ diet increased not only cardiac enlargement in SHR but also cardiac mass in normotensive rats without detectable change of arterial pressure. 31 Therefore, given the fact that NHE is a pathway for Na ϩ entry, its pharmacological blockade appears to be an intervention capable of reducing Na ϩ influx. An increased activity of the NHE has been detected in HF 32 and cariporide has been shown to have antiapoptotic effect
The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.that, as proposed by Humpreys et al, 33 could be of help in HF. It is not evident to us why, in the article by Engelhardt et al, 9 the regression of hypertrophy was accompanied by normalization (through a translational mechanism) of NHE activity after the blockade. This finding deserves further investigation but it is interesting that the regression of CH after antihypertensive treatment is also accompanied by normalization (through a posttranslational mechanism) of NHE activity in SHR. 34 Engelhardt et al 9 also reported fibrosis in accompanying CH in the mice overexpressing ␤ 1 -adrenergic receptors. However, neither fibrosis nor increases in myocardial stiffness has been detected in previous experiments 10 -13 in which hypertrophy is induced by isoproterenol. The possibility of "reparative fibrosis" instead of "reactive fibrosis" that characterizes the hypertensive hypertrophy was raised by the authors. Further studies about possible changes in diastolic compliance, collagen cross-linking, and/or accumulation of different collagen subtypes 35 
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